Compare BioNTech SE - ADR (BNTX) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Berkshire Hathaway Inc Class B — how do they compare? BioNTech SE - ADR trades at $90.47 (market cap $22.86B), while Berkshire Hathaway Inc Class B trades at $491.36. The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | BRK.B | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Financials |
52-Week High | $119.34 | $513.70 |
52-Week Low | $83.89 | $459.10 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
BRK.B trades at $491.11, down 1.14% today, with a bullish technical signal driven by moving averages and an oversold 6-day RSI of 14.57. Support levels are firm near $483-$489, while resistance sits at $495-$501. Analyst consensus is positive with 57% buy ratings, though key financial ratios are unavailable in the provided data.
The outlook remains constructive given strong analyst support and technical oversold conditions, but risks include market volatility and reliance on Berkshire Hathaway's diverse portfolio performance. Upside depends on earnings momentum and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
